Minerva Surgical (NASDAQ:UTRS – Get Free Report) will likely be announcing its resultson Tuesday, November 17th. Analysts expect Minerva Surgical to post earnings of ($8.8066) per share and revenue of $12.15 million for the quarter.
Minerva Surgical Price Performance
UTRS stock opened at $0.00 on Tuesday. The company has a market capitalization of $888.00, a PE ratio of -0.00 and a beta of 2.40. Minerva Surgical has a 1 year low of $0.00 and a 1 year high of $0.00.
About Minerva Surgical
Minerva Surgical, Inc is a medical device company focused on women’s health. The company develops and commercializes technologies intended to diagnose and treat conditions affecting the uterus, with an emphasis on abnormal uterine bleeding, a common condition that can significantly affect quality of life.
Its product portfolio includes the Minerva ES Endometrial Ablation System, which uses controlled energy to treat heavy menstrual bleeding, and the Symphion System, a hysteroscopic tissue-removal device used in procedures involving uterine fibroids and polyps.
See Also
- Five stocks we like better than Minerva Surgical
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
